| Literature DB >> 21921868 |
Bing-Feng Leng1, Jia-Zhang Qiu, Xiao-Han Dai, Jing Dong, Jian-Feng Wang, Ming-Jing Luo, Hong-En Li, Xiao-Di Niu, Yu Zhang, Yong-Xing Ai, Xu-Ming Deng.
Abstract
Staphylococcus aureus causes a broad range of life-threatening diseases in humans. The pathogenicity of this micro-organism is largely dependent upon its virulence factors. One of the most extensively studied virulence factors is the extracellular protein α-toxin. In this study, we show that allicin, an organosulfur compound, was active against S. aureus with MICs ranged from 32 to 64 μg/mL. Haemolysis, Western blot and real-time RT-PCR assays were used to evaluate the effects of allicin on S. aureus α-toxin production and on the levels of gene expression, respectively. The results of our study indicated that sub-inhibitory concentrations of allicin decreased the production of α-toxin in both methicillin-sensitive S. aureus (MSSA) and methicillin-resistant S. aureus (MRSA) in a dose-dependent manner. Furthermore, the transcriptional levels of agr (accessory gene regulator) in S. aureus were inhibited by allicin. Therefore, allicin may be useful in the treatment of α-toxin-producing S. aureus infections.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21921868 PMCID: PMC6264299 DOI: 10.3390/molecules16097958
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Bacterial strains used in the study and their MICs to allicin.
| S. aureus strains | Description | Source | MIC (μg/mL) | |
|---|---|---|---|---|
| Oxacillin | Allicin | |||
| ATCC 29213 | β-Lactamase-producing oxacillin-susceptible strain, α-toxin-producing strain | ATCC | 0.25 | 64 |
| ATCC 10832 | Wood 46, a natural isolate that produces high levels of α-toxin | ATCC | 0.125 | 64 |
| BAA-1717 | USA300-HOU-MR, Isolated from adolescent patient with severe sepsis syndrome in Texas Children's Hospital, α-toxin-producing strain | ATCC | 256 | 64 |
| 8325-4 | A high-level α-toxin-producing strain derived from NCTC 8325 | Timothy J. Foster | 0.125 | 64 |
| DU 1090 | α-toxin-negative mutant of | Timothy J. Foster | 0.125 | 32 |
| ATCC 25923 | A clinical isolate collected at Seattle in 1945 | ATCC | 0.25 | 32 |
Figure 1Growth curves of S. aureus strain ATCC 29213 treated with different concentrations of allicin. (◆), untreated S. aureus; (■), S. aureus plus allicin at 2 μg/mL; (▲), S. aureus plus allicin at 4 μg/mL; (×), S. aureus plus allicin at 8 μg/mL; and (*), S. aureus plus allicin at 16 μg/mL; (●), S. aureus plus allicin at 64 μg/mL.
Haemolysis of S. aureus culture supernatants treated with increasing concentrations of allicin.
| Haemolysis (%) of rabbit erythrocytes by culture supernatant a | |||||
|---|---|---|---|---|---|
| Strains | 0 | 2 μg/mL | 4 μg/mL | 8 μg/mL | 16 μg/mL |
| 8325-4 | 100 | 96.5 ± 3.0 | 75.1 ± 4.9 * | 64.3 ± 4.1 * | 22.1 ± 4.0 * |
| ATCC 29213 | 100 | 89.2 ± 4.5 | 62.5 ± 4.4 | 36.5 ± 5.1 * | 15.6 ± 3.5 ** |
| ATCC 10832 | 100 | 64.1 ± 4.7 | 43.2 ± 3.7 * | 30.0 ± 3.9 * | NO |
| BAA-1717 | 100 | 90.7 ± 5.2 | 58.1 ± 4.4 * | 24.3 ± 4.7 * | 6.23 ± 3.2 ** |
a The culture supernatants without allicin served as the 100% haemolysis control. NO represents that there was no observed haemolytic activity. Values represent the mean and standard deviation of three independent experiments. * indicates p < 0.05 and ** indicates p < 0.01, when compared with the corresponding control.
Figure 2Western blot analysis of α-toxin production by strain ATCC 29213 (A) and BAA-1717 (B) after treatment with different concentrations of allicin.
Figure 3Protease units of S. aureus culture supernatants after treatment with allicin. Values represent the mean ± SD for three independent experiments.
Figure 4Effectsof different concentrations of allicin on the transcription of hla and agrA in S. aureus. Data are expressed as the means ± SD for three independent experiments. The Student’s t-test was used to determine statistical differences. * Indicates p < 0.05 and ** indicates p < 0.01 vs. control.
Primers used in real-time RT-PCR.
| Primer | Sequence | Location within gene |
|---|---|---|
|
| 5'-GCTGCCCTTTGTATTGTC-3' | 287–305 |
|
| 5'-AGATGTTGGGTTAAGTCCC-3' | 446–465 |
|
| 5'-TTGGTGCAAATGTTTC-3' | 485–501 |
|
| 5'-TCACTTTCCAGCCTACT-3' | 569–586 |
|
| 5'-TGATAATCCTTATGAGGTGCTT-3' | 111–133 |
|
| 5'-CACTGTGACTCGTAACGAAAA-3' | 253–274 |